DMC will undertake a major marketing campaign beginning in August 2017 for the Nugen™ syringe range. The prefilled drug market is seeking alternatives to glass syringes/vials with suitable polymers that are BPA free, chemical & lipid resistant with added toughness and glass-like clarity. The Nugen™ syringe is a suitable and cost-effective alternative. DMC will target the major pharma companies in both Europe and the United States currently prefilling drugs and seeking a superior polymer syringe.

The SureSafe™ 3ml automatic retractable syringe receives its first approval for the vaccination market in the U.S.

Enquiries increase for the BPA Free Nugen™ syringe with evaluation samples going to the United Kingdom, Turkey, Spain, Russia and the United States. Validations can take a number of months depending on what use the syringe is put to and the drug involved.

In collaboration with the materials science department of the University of Limerick and a leading materials scientist in the U.K., DMC is conducting a series of tooling and material experiments in the coating of syringe stoppers suitable for the prefilled drug market.

As a result of its classification as “reprotox 1B”, which entered into force in August 2016, BPA formally meets the criteria for identification as a Substance of Very High Concern. In December 2016, ECHA’s Member State Committee (MSC) agreed to identify BPA as SVHC, based on its harmonised classification.

The California Office of Environmental Health Hazard Assessment (OEHHA) lists BPA under Proposition 65 Warnings.

DMC is currently undertaking trials, which addressed the levels of silicone oil used to lubricate the barrel/stopper in the prefilled drug market. The free suspension of oil is an ongoing issue and one that DMC will reduce/eliminate during trials – September 2016

DMC’s copolyester BPA free syringe is gaining traction in the market amongst the Kit Packers and Prefilled Drug providers, where we are seeing an increased demand month on month – August 2016

DMC undertakes the development of a heart positioning device that will complement its current cardiovascular accessory portfolio for open heart surgery – April 2016

CE mark approval for the SureSafe™ received on the 14th April 2016

DMC undertakes the development of a customer specified syringe range for the European/Australian markets. DMC will deliver to the rest of the world – March 2016

Agents appointed for Hong Kong, Singapore, Japan, Mexico, UAE, Iran, Saudi Arabia, New Zealand, Iraq & Kuwait – March 2016

First deliveries of SureSafe™ to Carson CA in February 2016.

During 2015 DMC entered a joint collaboration with Eastman Chemical and a major Multi-National in trialling the NuGen™ for a new prefilled drug delivery syringe. An extensive report was issued on the trials with NuGen™ being the syringe of choice – December 2015

PCT patent application for the SureSafe™ automatic retractable syringe range – June 2015.

FDA 510K approval for the Automatic Retractable Syringe “Options” in November 2015.

The latter part of 2014 and the first half of 2015 were spent further developing and perfecting the SureSafe™ range of automatic retractable syringes (1ml, 3ml, 5ml & 10ml). This development is now complete – July 2015

Pat Jones is appointed as Financial Director at DMC medical – April 2015.